Distribution of natural resistance to NS3 protease inhibitors in hepatitis C genotype 1a separated into clades 1 and 2 and in genotype 1b of HIV-infected patients

S. Bagaglio; Caterina Uberti Foppa; E. Messina; M. Merli; H. Hasson; A. Andolina; A. Galli; A. Lazzarin; Giulia Morsica

doi:10.1016/j.cmi.2015.12.007

Distribution of natural resistance to NS3 protease inhibitors in hepatitis C genotype 1a separated into clades 1 and 2 and in genotype 1b of HIV-infected patients

S. Bagaglio, Caterina Uberti Foppa, E. Messina, M. Merli, H. Hasson, A. Andolina, A. Galli, A. Lazzarin, Giulia Morsica

IRCCS Ospedale San Raffaele

Research output: Contribution to journal › Article › peer-review

Abstract

Naturally occurring resistance-associated variants (RAVs) within the protease domain of hepatitis C virus (HCV) genotype (G) 1a separated into clades 1 and 2, and G1b were investigated in 59 HIV/HCV coinfected patients. RAVs were detected in 10/23 G1a/clade 1 and 1/19 G1b (p 0.0059). A similar frequency of RAVs was found when comparing G1a/clade 2 and G1b (p 0.1672). A cross-resistance to the macrocyclic compounds simeprevir and paritaprevir was detected in two G1a/clade 2 and 1 G1b sequences and none of G1a/clade 1 sequences. The simultaneous characterization of subtype and natural RAVs by population analysis of the NS3 domain by may add important information for anti-HCV treatment strategies including protease inhibitors.

Original language	English
Pages (from-to)	386.e1 - 386.e3
Journal	Clinical Microbiology and Infection
Volume	22
Issue number	4
DOIs	https://doi.org/10.1016/j.cmi.2015.12.007
Publication status	Published - Apr 1 2016

Keywords

Clades 1 and 2
Genotype 1a
HCV-PI
HIV
Natural RAV
Q80K polymorphism

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases

Access to Document

10.1016/j.cmi.2015.12.007

Cite this

Bagaglio, S., Uberti Foppa, C., Messina, E., Merli, M., Hasson, H., Andolina, A., Galli, A., Lazzarin, A., & Morsica, G. (2016). Distribution of natural resistance to NS3 protease inhibitors in hepatitis C genotype 1a separated into clades 1 and 2 and in genotype 1b of HIV-infected patients. Clinical Microbiology and Infection, 22(4), 386.e1 - 386.e3. https://doi.org/10.1016/j.cmi.2015.12.007

Distribution of natural resistance to NS3 protease inhibitors in hepatitis C genotype 1a separated into clades 1 and 2 and in genotype 1b of HIV-infected patients. / Bagaglio, S.; Uberti Foppa, Caterina; Messina, E. et al.

In: Clinical Microbiology and Infection, Vol. 22, No. 4, 01.04.2016, p. 386.e1 - 386.e3.

Research output: Contribution to journal › Article › peer-review

Bagaglio, S, Uberti Foppa, C, Messina, E, Merli, M, Hasson, H, Andolina, A, Galli, A, Lazzarin, A & Morsica, G 2016, 'Distribution of natural resistance to NS3 protease inhibitors in hepatitis C genotype 1a separated into clades 1 and 2 and in genotype 1b of HIV-infected patients', Clinical Microbiology and Infection, vol. 22, no. 4, pp. 386.e1 - 386.e3. https://doi.org/10.1016/j.cmi.2015.12.007

@article{bacc2482279d40db9835206c6492432f,

title = "Distribution of natural resistance to NS3 protease inhibitors in hepatitis C genotype 1a separated into clades 1 and 2 and in genotype 1b of HIV-infected patients",

abstract = "Naturally occurring resistance-associated variants (RAVs) within the protease domain of hepatitis C virus (HCV) genotype (G) 1a separated into clades 1 and 2, and G1b were investigated in 59 HIV/HCV coinfected patients. RAVs were detected in 10/23 G1a/clade 1 and 1/19 G1b (p 0.0059). A similar frequency of RAVs was found when comparing G1a/clade 2 and G1b (p 0.1672). A cross-resistance to the macrocyclic compounds simeprevir and paritaprevir was detected in two G1a/clade 2 and 1 G1b sequences and none of G1a/clade 1 sequences. The simultaneous characterization of subtype and natural RAVs by population analysis of the NS3 domain by may add important information for anti-HCV treatment strategies including protease inhibitors.",

keywords = "Clades 1 and 2, Genotype 1a, HCV-PI, HIV, Natural RAV, Q80K polymorphism",

author = "S. Bagaglio and {Uberti Foppa}, Caterina and E. Messina and M. Merli and H. Hasson and A. Andolina and A. Galli and A. Lazzarin and Giulia Morsica",

year = "2016",

month = apr,

day = "1",

doi = "10.1016/j.cmi.2015.12.007",

language = "English",

volume = "22",

pages = "386.e1 -- 386.e3",

journal = "Clinical Microbiology and Infection",

issn = "1198-743X",

publisher = "Elsevier B.V.",

number = "4",

}

TY - JOUR

T1 - Distribution of natural resistance to NS3 protease inhibitors in hepatitis C genotype 1a separated into clades 1 and 2 and in genotype 1b of HIV-infected patients

AU - Bagaglio, S.

AU - Uberti Foppa, Caterina

AU - Messina, E.

AU - Merli, M.

AU - Hasson, H.

AU - Andolina, A.

AU - Galli, A.

AU - Lazzarin, A.

AU - Morsica, Giulia

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Naturally occurring resistance-associated variants (RAVs) within the protease domain of hepatitis C virus (HCV) genotype (G) 1a separated into clades 1 and 2, and G1b were investigated in 59 HIV/HCV coinfected patients. RAVs were detected in 10/23 G1a/clade 1 and 1/19 G1b (p 0.0059). A similar frequency of RAVs was found when comparing G1a/clade 2 and G1b (p 0.1672). A cross-resistance to the macrocyclic compounds simeprevir and paritaprevir was detected in two G1a/clade 2 and 1 G1b sequences and none of G1a/clade 1 sequences. The simultaneous characterization of subtype and natural RAVs by population analysis of the NS3 domain by may add important information for anti-HCV treatment strategies including protease inhibitors.

AB - Naturally occurring resistance-associated variants (RAVs) within the protease domain of hepatitis C virus (HCV) genotype (G) 1a separated into clades 1 and 2, and G1b were investigated in 59 HIV/HCV coinfected patients. RAVs were detected in 10/23 G1a/clade 1 and 1/19 G1b (p 0.0059). A similar frequency of RAVs was found when comparing G1a/clade 2 and G1b (p 0.1672). A cross-resistance to the macrocyclic compounds simeprevir and paritaprevir was detected in two G1a/clade 2 and 1 G1b sequences and none of G1a/clade 1 sequences. The simultaneous characterization of subtype and natural RAVs by population analysis of the NS3 domain by may add important information for anti-HCV treatment strategies including protease inhibitors.

KW - Clades 1 and 2

KW - Genotype 1a

KW - HCV-PI

KW - HIV

KW - Natural RAV

KW - Q80K polymorphism

UR - http://www.scopus.com/inward/record.url?scp=84960153962&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960153962&partnerID=8YFLogxK

U2 - 10.1016/j.cmi.2015.12.007

DO - 10.1016/j.cmi.2015.12.007

M3 - Article

VL - 22

SP - 386.e1 - 386.e3

JO - Clinical Microbiology and Infection

JF - Clinical Microbiology and Infection

SN - 1198-743X

IS - 4

ER -

Distribution of natural resistance to NS3 protease inhibitors in hepatitis C genotype 1a separated into clades 1 and 2 and in genotype 1b of HIV-infected patients

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this